Production of interleukin-10 in asthmatic children after Beta-1-3-glucan

Production of interleukin-10 in asthmatic children after Beta-1-3-glucan

Author Sarinho, E. Google Scholar
Medeiros, D. Google Scholar
Schor, D. Google Scholar
Silva, A. Rego Google Scholar
Sales, V. Google Scholar
Motta, M. E. Google Scholar
Costa, A. Google Scholar
Azoubel, A. Autor UNIFESP Google Scholar
Rizzo, J. A. Google Scholar
Institution Universidade Federal de Pernambuco (UFPE)
Univ Fed Rio Grande do Sul
Universidade Federal de São Paulo (UNIFESP)
Abstract Background: Beta-1-3 Glucan is a polysaccharide extracted from Saccharomyces cerevisiae with a possible immunomodulating action that may have a favourable action on asthma symptoms and other allergic diseases. An experimental study carried out using a murine respiratory model detected a decrease in pulmonary tissue eosinophilia, as well as an increase in Interleukin-10 (IL-10) after glucan use.Methods: This open, exploratory study with blind outcome evaluation included asthmatic children between 6 and 12 years of age with mild to moderate persistent asthma and inadequate disease control (rescue medication needed more than twice a week) in spite of inhaled budesonide 400 mu g/day. After a four week run-in period, subcutaneous Beta-1-3-glucan injections were given weekly for the first four weeks and then every two weeks for the last four weeks. IL-10 levels, measured by the immunoenzymatic method (ELISA), were compared before and after glucan administration.Results: Twenty patients (14 male and 6 female) were included. Mean IL-10 levels were 6.4 pg/ml and 11.3 pg/ml before and after glucan, respectively (p = 0.02). There was also a reduction of asthmatic symptoms score at the end of study.Conclusions: This is the first study which shows that subcutaneous particulate Beta-1-3-glucan increases serum IL-10 levels in asthmatics. the possibility of glucan being able to modulate allergic sensitisation and having a beneficial action in restoring Th2 function should be assessed by means of property planned controlled clinical trials, as it may represent a new therapeutic strategy. (C) 2008 SEICAP. Published by Elsevier Espana, S.L. All rights reserved.
Keywords Allergy
Asthma. Glucan
Immunomodulation
Interleukin-10
Language English
Date 2009-07-01
Published in Allergologia Et Immunopathologia. Barcelona: Elsevier Doyma Sl, v. 37, n. 4, p. 188-192, 2009.
ISSN 0301-0546 (Sherpa/Romeo, impact factor)
Publisher Elsevier B.V.
Extent 188-192
Origin http://dx.doi.org/10.1016/j.aller.2009.02.005
Access rights Closed access
Type Article
Web of Science ID WOS:000271035500004
URI http://repositorio.unifesp.br/handle/11600/31637

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account